Market Overview

Jefferies Sees Accelerated Approval Of Immunomedics' IMMU-132 'Not A Stretch'


Jefferies assumed coverage of Immunomedics, Inc. (NASDAQ: IMMU) with a Buy rating and $5.50 price target, saying shares are undervalued ahead of a partnership announcement on IMMU-132.

The company is in the process of completing various activities to support the Phase III study of sacituzumab govitecan (SG) in metastatic 3rd-Line triple-negative breast cancer (TNBC).

IMMU-132 has generated promising results in TNBC and the brokerage believes clinical/registration/CMC progress in 2016 sets the stage for a deal in the coming months ahead of Ph. III start by late 2016/early 2017.

Andrews expects a global partnership by first quarter 2017 and is driven by IMMU's progress on key issues during 2016.

"Based on '132's TNBC profile and FDA precedent, we assign a 55% probability of Accelerated Approval (AA) based on Ph. II data in 2018," analyst Matthew Andrews wrote in a note.

The analyst pointed out that FDA has approved Breakthrough Therapy Designation (BTD) designees Keytruda, Alecensa, Opdivo, Darzalex, Tagrisso, and Imbruvica based on objective response rate (ORR) and duration of response (DOR), via the accelerated approval pathway.

"While this regulatory precedent is applicable to SG in TNBC, ultimately the robustness of the 100+ patient dataset and FDA's comfort around CMC issues will drive its evidence-based decision," Andrews highlighted.

The analyst anticipates a 2018 launch in the US and a 2022 launch in the EU based on progression-free survival data and expects shares to trade up on an announcement of a "good" deal as it would remove a near-term overhang on shares.

Latest Ratings for IMMU

Aug 2020Morgan StanleyMaintainsEqual-Weight
Aug 2020Piper SandlerMaintainsOverweight
Aug 2020B of A SecuritiesMaintainsBuy

View More Analyst Ratings for IMMU
View the Latest Analyst Ratings


Related Articles (IMMU)

View Comments and Join the Discussion!

Posted-In: Jefferies Matthew AndrewsAnalyst Color Price Target Initiation Analyst Ratings

Latest Ratings

ZTSGabelli & Co.Downgrades
AUPHHC Wainwright & Co.Maintains34.0
RCLCredit SuisseMaintains75.0
PINCCredit SuisseMaintains35.0
SUNCredit SuisseMaintains29.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at